Apellis Medical Hub
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Retina Fellow Research Grant
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
  • Menu Menu
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Retina Fellow Research Grant
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.

Retina Fellow Research Grant

US Retina Fellow Research Grant

Apellis is committed to improving the lives of patients with geographic atrophy (GA) secondary to AMD and supports medical and scientific research that demonstrates the highest standards of scientific integrity, inclusivity, and intellectual curiosity.

Apellis is offering a research grant of up to $50,000, awarded based on its scientific merit and impact on patients. Research applications should have the following scientific focus:

  • Imaging and diagnostic strategies for GA
  • Real-world insights on pegcetacoplan efficacy and safety
  • Pegcetacoplan in underrepresented patient phenotypes
  • Pegcetacoplan dosing strategies
  • Studies or tests to evaluate visual function in patients with GA
  • Further understanding of the relationship between GA and neovascularization in AMD
  • Biomarkers in GA to assess disease progression/treatment response

Application Requirements

Applications must be submitted through the online submission portal linked below. The following information is required for the US Retina Fellows Grant application submission:

  • Proof of enrollment in a US based vitreoretinal/medical retina fellowship program
  • Supporting documentation (i.e., CV) for the applicant and the applicant’s director/mentor
  • Research Plan

Review Process

Applications to the US Retina Fellow Research Grant will be reviewed on a rolling basis up until the submission deadline. Following a selection of top applications by the US GA Medical Director Team, a steering committee of US Retina Specialists will review the finalists in a de-identified fashion based on the research merit criteria.

Timeline 

The submission portal will be open for applications up to August 28, 2026 at 11:59 PM ET. Following closure of the submission portal on August 28, applications will be reviewed as outlined above. The process is anticipated to take 3-4 weeks, at which point the applicant with the selected submission will be notified. Following confirmation with the applicant, an announcement will be made regarding the selected project.

Apply now for the Retina Fellow Grant

Report an Adverse Event or Product complaint

Please call 833-866-3346

Ask a Medical Question

Please click here or call
833-866-3346 (833-TO-MEDINFO)

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and Conditions

©2025 Apellis Pharmaceuticals, Inc. All rights reserved. 08/25 MED-US-CORP-22-00001 v14.0
Scroll to top

Geographic Atrophy Risk Calculator Important Usage Information

Intended Use

•  This Geographic Atrophy (GA) Risk Calculator is only intended for disease state awareness and for use by an eye doctor to understand the factors for disease progression. This is not a diagnostic tool or a tool to assist in treatment selection.

•  All decisions about patient care and diagnosis shall be made by a patient’s physician using his or her independent clinical judgment.

•  The GA Risk Calculator predicts a potential 5-year risk of outcomes for a GA patient (time to severe visual impairment (Snellen 20/200) and time to subfoveal involvement). This tool was developed utilizing risk equations using retrospective electronic health records of GA data from Cleveland Clinic patients (n=410). Statistical tests identified the most prominent predictors for time to severe visual impairment prediction as baseline visual acuity, subfoveal lesion, age, sex, smoking, fellow eye GA and select comorbidities. Validation was conducted using the Sham arms of Oaks (ClinicalTrials.gov, NCT03525613) and Derby (NCT03525600) trials. There is no treatment-related data incorporated in the tool nor is this tool intended to make any treatment assessments or recommendations.

•  The risk calculator being presented is for illustrative purposes only. Patient disease experience and/or progression may vary and depends on many individual factors including, but not limited to, the patient’s clinical history.

Limitations

•  Patients enrolled in clinical trials are expected to differ from those seen in routine clinical practice on important risk factors, such as time from GA onset and other severity measures.

•  More frequent data collection during clinical trials (monthly) than routine practice (~quarterly) could impact estimates of time to event outcomes.

•  The risk calculator predicts 5-year outcomes. However, the rate of progression on these outcomes can change with time within those 5-years.

•  These calculated predictions do not guarantee onset of identified outcomes.

Proceed to GA Risk Calculator

Developed by Apellis Pharmaceuticals, Inc. in collaboration with The Cleveland Clinic Foundation

Landing

Landing

You are entering a website that is technical in nature and was created for scientific exchange with Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.
Are you a Healthcare Professional licensed to practice in the country or region selected above? If you are not a Healthcare Professional, you will be redirected to www.apellis.com(Required)
Enter
Enter
Enter
Enter
Enter
Enter

You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree